Repositioning Candidate Details
| Candidate ID: | R1396 |
| Source ID: | DB11721 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | Mitoglitazone |
| Synonyms: | MSDC-0160 |
| Molecular Formula: | C19H18N2O4S |
| SMILES: | CCC1=CN=C(C=C1)C(=O)COC1=CC=C(CC2SC(=O)NC2=O)C=C1 |
| Structure: |
|
| DrugBank Description: | Mitoglitazone has been used in trials studying the treatment of Type 2 Diabetes and Alzheimer's Disease. |
| CAS Number: | 146062-49-9 |
| Molecular Weight: | 370.422 |
| DrugBank Indication: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | -- |
| Targets: | Peroxisome proliferator-activated receptor gamma |
| Inclusion Criteria: | Target associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |